Leadership Story

Inspiring Vision, Driving Innovation.

At JY BioMed, our leadership is guided by a clear vision: to transform scientific breakthroughs into meaningful healthcare solutions. Our leadership stories highlight the people behind our innovation—sharing their perspectives, experiences, and the strategic thinking that drives our progress. Through these stories, we offer insights into our decision-making, our commitment to scientific excellence, and the values that shape our organization. From advancing novel therapeutic platforms to navigating complex regulatory landscapes, our leaders are dedicated to building a future where cutting-edge science translates into real-world impact.

Stay connected to learn more about the vision, expertise, and leadership shaping JY BioMed’s journey.

Cultivation Meets Enterprise: The Dual Life of Dr. Ethan Shen, Founder of JY BioMed

Discover how Dr. Ethan Shen, Founder & Chairman of JY BioMed, merges spiritual practice with biotech innovation — driven by a vow to advance cancer immunotherapy research in Taiwan and beyond.

Leadership Story

1 day ago

The Origin of JY BioMed: From a Pharmacy in Wanhua to Cell Therapy and Biotech Innovation

From a small pharmacy in Wanhua, Dr. Ethan Shen led JY BioMed into cell therapy and regenerative medicine—advancing biotech innovation and new possibilities in cancer treatment.

Leadership Story

Apr 17

JY BioMed’s GDT Platform Published in International Journal; Secures US$38M Licensing and Expands into Nasdaq Cell Therapy Ecosystem

JY BioMed Co., Ltd. is proud to announce the publication of its latest research in the internationally renowned journal Cancer Letters, highlighting a novel antibody-drug conjugate (ADC) platform targeting CEACAM6 for the treatment of aggressive cancers, including brain metastases.

Company News & Media

Apr 10

JY BioMed Announces Publication in Cancer Letters: Novel Heavy-Chain ADC Demonstrates Breakthrough Efficacy Against Brain Metastases

Scientific Insights

Apr 7

JY BioMed Announces Publication of Breakthrough Preclinical Study on Unmodified Gamma Delta T Cell Therapy for Liver Cancer

Ji Yan Biomedical Co., Ltd. (JY BioMed), a biotechnology company focused on next-generation cell-based immunotherapies, today announced the publication of a landmark preclinical study demonstrating the potent antitumor activity of unmodified gamma delta (γδ) T cells in hepatocellular carcinoma (HCC).

Scientific Insights

Feb 5

2 3 4 5

Regulatory Disclaimer

Participation in events and conferences is for scientific, educational, and informational purposes. Information presented may include exploratory or investigational content not approved for clinical or commercial use.

< Back